


Human sCD162 (sPSGL-1) ELISA Kit



Instruction Manual

PromoKine

Contents

1. Intended Use	3
2. Summary	3
3. Principles of the Test	4
4. Reagents Provided	6
5. Storage Instructions – ELISA Kit	6
6. Specimen Collection and Storage Instructions	7
7. Materials Required But Not Provided	7
8. Precautions for Use	8
9. Preparation of Reagents	9
10. Test Protocol	13
11. Calculation of Results	18
12. Limitations	21
13. Performance Characteristics	21
14. Bibliography	26
15. Reagent Preparation Summary	31
16. Test Protocol Summary	32
17. Ordering Information	33

1. Intended Use

The human sPSGL-1 ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human PSGL-1. **The human sPSGL-1 ELISA is for research use only. Not for diagnostic or therapeutic procedures.**

2. Summary

The family of selectins consists of three structurally and functionally related molecules. L-selectin is constitutively expressed on neutrophils, P-selectin is found on platelets and is stored in Weibel-Palade bodies from where it is transported to the cell surface upon endothelial activation. E-selectin is expressed on endothelial cells. Due to a common structural element, the amino-terminal lectin-like domain, the selectins are able to bind to carbohydrate ligands. Different putative ligand structures have been identified for which the selectins show high affinity. These structures include oligosaccharides, phosphorylated saccharides, sulfopolysaccharides and lipids.

It was shown that glycoproteins represent the biological relevant ligands for selectins. While the ligands for E- and L-selectins with primary binding activity have not been identified so far, the functionally most important ligand for P-selectin has been identified. The mucin-like glycoprotein PSGL-1 (P-selectin Glycoprotein Ligand-1) has been cloned and sequenced.

PSGL-1 has been shown to be a transmembrane protein which forms homodimers via disulfide bridges of two 120 kDa chains.

PSGL-1 is expressed on cells of myeloid, lymphoid and dendritic lineage. The binding of P-selectin is regulated by different degrees and forms of glycosylation. An interaction of L-selectin with PSGL-1 in the process of neutrophil aggregation has been shown. However, PSGL-1 does not seem to be the primary ligand for L-selectin.

Presently it is not known which cells, apart from leukocytes, express PSGL-1 and what role PSGL-1 plays on these cells. The metastatic potential of the majority of cells which bind to P-selectin is however in close correlation with the functional expression of PSGL-1 on these cells.


The regulation of PSGL-1 is not yet well described. Glycosyltransferases sure play an important role in activation. The deactivation of PSGL-1 is so far unclear. The cleavage of the protein from the cell surface is one mechanism involved in the deactivation process.

Following this shedding, a soluble form of PSGL-1 is detectable in the circulation. This soluble isoform of PSGL-1 is still capable of binding to P-selectin, thus representing a competitor for cellular PSGL-1 through which regulation in many physiological and pathological processes can take place.

3. Principles of the Test


An anti-human PSGL-1 coating antibody is adsorbed onto microwells.

Figure 1




Human PSGL-1 present in the sample or standard binds to antibodies adsorbed to the microwells. A biotin-conjugated anti-human PSGL-1 antibody is added and binds to human PSGL-1 captured by the first antibody.

Figure 2




Following incubation unbound biotin-conjugated anti-human PSGL-1 antibody is removed during a wash step. Streptavidin-HRP is added and binds to the biotin-conjugated anti-human PSGL-1 antibody.

Figure 3




Following incubation unbound Streptavidin-HRP is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

Figure 4



A coloured product is formed in proportion to the amount of human PSGL-1 present in the sample or standard. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from 6 human PSGL-1 standard dilutions and human PSGL-1 sample concentration determined.

Figure 5



4. Reagents Provided

Reagents for human PSGL-1 ELISA Kit (96 tests)

- 1 aluminium pouch with a **Microwell Plate coated** with monoclonal antibody to human PSGL-1
- 1 vial (100 µl) **Biotin-Conjugate** anti-human PSGL-1 monoclonal antibody
- 1 vial (150 µl) **Streptavidin-HRP**
- 2 vials human PSGL-1 **Standard** lyophilized, 100 U/ml upon reconstitution
- 1 vial (50 ml) **Sample Diluent**
- 1 vial (5 ml) **Assay Buffer Concentrate** 20x (PBS with 1% Tween 20 and 10% BSA)
- 1 bottle (50 ml) **Wash Buffer Concentrate** 20x (PBS with 1% Tween 20)
- 1 vial (15 ml) **Substrate Solution** (tetramethyl-benzidine)
- 1 vial (12 ml) **Stop Solution** (1M Phosphoric acid)
- 1 vial (0.4 ml) **Blue-Dye**
- 1 vial (0.4 ml) **Green-Dye**
- 1 vial (0.4 ml) **Red-Dye**
- 4 **Adhesive Films**

5. Storage Instructions – ELISA Kit

Store kit reagents between 2°C and 8°C. Immediately after use remaining reagents should be returned to cold storage (2°C to 8°C). Expiry of the kit and reagents is stated on labels.

Expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, this reagent is not contaminated by the first handling.

6. Specimen Collection and Storage Instructions

Cell culture supernatant and serum were tested with this assay. Other biological samples might be suitable for use in the assay. Remove serum from the clot as soon as possible after clotting.

Pay attention to a possible **“Hook Effect”** due to high sample concentrations (see chapter 11).

Samples containing a visible precipitate must be clarified prior to use in the assay. Do not use grossly hemolyzed or lipemic specimens.

Samples should be aliquoted and must be stored frozen at -20°C to avoid loss of bioactive human PSGL-1. If samples are to be run within 24 hours, they may be stored at 2° to 8°C (for sample stability refer to 13.5.).

Avoid repeated freeze-thaw cycles. Prior to assay, the frozen sample should be brought to room temperature slowly and mixed gently.

7. Materials Required But Not Provided

- 5 ml and 10 ml graduated pipettes
- 5 µl to 1000 µl adjustable single channel micropipettes with disposable tips
- 50 µl to 300 µl adjustable multichannel micropipette with disposable tips
- Multichannel micropipette reservoir
- Beakers, flasks, cylinders necessary for preparation of reagents
- Device for delivery of wash solution (multichannel wash bottle or automatic wash system)
- Microwell strip reader capable of reading at 450 nm (620 nm as optional reference wave length)
- Glass-distilled or deionized water
- Statistical calculator with program to perform regression analysis

8. Precautions for Use

- All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.
- Reagents are intended for research use only and are not for use in diagnostic or therapeutic procedures.
- Do not mix or substitute reagents with those from other lots or other sources.
- Do not use kit reagents beyond expiration date on label.
- Do not expose kit reagents to strong light during storage or incubation.
- Do not pipette by mouth.
- Do not eat or smoke in areas where kit reagents or samples are handled.
- Avoid contact of skin or mucous membranes with kit reagents or specimens.
- Rubber or disposable latex gloves should be worn while handling kit reagents or specimens.
- Avoid contact of substrate solution with oxidizing agents and metal.
- Avoid splashing or generation of aerosols.
- In order to avoid microbial contamination or cross-contamination of reagents or specimens which may invalidate the test use disposable pipette tips and/or pipettes.

- Use clean, dedicated reagent trays for dispensing the conjugate and substrate reagent.
- Exposure to acid inactivates the conjugate.
- Glass-distilled water or deionized water must be used for reagent preparation.
- Substrate solution must be at room temperature prior to use.
- Decontaminate and dispose specimens and all potentially contaminated materials as they could contain infectious agents. The preferred method of decontamination is autoclaving for a minimum of 1 hour at 121.5°C.
- Liquid wastes not containing acid and neutralized waste may be mixed with sodium hypochlorite in volumes such that the final mixture contains 1.0% sodium hypochlorite. Allow 30 minutes for effective decontamination. Liquid waste containing acid must be neutralized prior to the addition of sodium hypochlorite.

9. Preparation of Reagents

Buffer Concentrates should be brought to room temperature and should be diluted before starting the test procedure. If crystals have formed in the **Buffer Concentrates**, warm them gently until they have completely dissolved.

9.1. Wash Buffer (1x)

Pour entire contents (50 ml) of the **Wash Buffer Concentrate** (20x) into a clean 1000 ml graduated cylinder. Bring to final volume of 1000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. The pH of the final solution should adjust to 7.4.

Transfer to a clean wash bottle and store at 2°C to 25°C. Please note that Wash Buffer (1x) is stable for 30 days.

Wash Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Wash Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

9.2. Assay Buffer (1x)

Pour the entire contents (5 ml) of the **Assay Buffer Concentrate** (20x) into a clean 100 ml graduated cylinder. Bring to final volume of 100 ml with distilled water. Mix gently to avoid foaming.

Store at 2°C to 8°C. Please note that the Assay Buffer (1x) is stable for 30 days.

Assay Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Assay Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 - 6	2.5	47.5
1 - 12	5.0	95.0

9.3. Biotin-Conjugate

Please note that the Biotin-Conjugate should be used within 30 minutes after dilution.

Make a 1:100 dilution of the concentrated **Biotin-Conjugate** solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

Number of Strips	Biotin-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.03	2.97
1 - 12	0.06	5.94

9.4. Streptavidin-HRP

Please note that the Streptavidin-HRP should be used within 30 minutes after dilution.

Make a 1:200 dilution of the concentrated **Streptavidin-HRP** solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

Number of Strips	Streptavidin-HRP (ml)	Assay Buffer (1x) (ml)
1 - 6	0.03	5.97
1 - 12	0.06	11.94

9.5. Human PSGL-1 Standard

Reconstitute **human PSGL-1 standard** by addition of distilled water. Reconstitution volume is stated on the label of the standard vial. Swirl or mix gently to insure complete and homogeneous solubilisation (concentration of reconstituted standard = 100 U/ml). After usage remaining standard cannot be stored and has to be discarded.

Standard dilutions can be prepared directly on the microwell plate (see 10.d) or alternatively in tubes (see 9.5.1.).

9.5.1. External Standard Dilution

Label 6 tubes, one for each standard point.

S1, S2, S3, S4, S5, S6

Then prepare 1:2 serial dilutions for the standard curve as follows:

Pipette 225 µl of Sample Diluent into each tube.


Pipette 225 µl of reconstituted standard (concentration = 100 U/ml) into the first tube, labelled S1, and mix (concentration of standard 1 = 50 U/ml).

Pipette 225 µl of this dilution into the second tube, labelled S2, and mix thoroughly before the next transfer.

Repeat serial dilutions 4 more times thus creating the points of the standard curve (see Figure 6).

Sample Diluent serves as blank.

Figure 6



9.6. Addition of Colour-giving Reagents: Blue-Dye, Green-Dye, Red-Dye

In order to help our customers to avoid any mistakes in pipetting the PromoKine ELISAs, PromoCell offers a tool that helps to monitor the addition of even very small volumes of a solution to the reaction well by giving distinctive colours to each step of the ELISA procedure.

This procedure is optional, does not in any way interfere with the test results, and is designed to help the customer with the performance of the test, but can also be omitted, just following the instruction booklet.

Alternatively, the dye solutions from the stocks provided (**Blue-Dye**, **Green-Dye**, **Red-Dye**) can be added to the reagents according to the following guidelines:

- Diluent:** Before standard and sample dilution add the **Blue-Dye** at a dilution of 1:250 (see table below) to the appropriate diluent (1x) according to the test protocol. After addition of **Blue-Dye**, proceed according to the instruction booklet.

5 ml Sample Diluent	20 µl Blue-Dye
12 ml Sample Diluent	48 µl Blue-Dye
50 ml Sample Diluent	200 µl Blue-Dye

- Biotin-Conjugate:** Before dilution of the concentrated Biotin-Conjugate, add the **Green-Dye** at a dilution of 1:100 (see table below) to the Assay Buffer (1x) used for the final conjugate dilution. Proceed after addition of **Green-Dye** according to the instruction booklet: Preparation of Biotin-Conjugate.

3 ml Assay Buffer (1x)	30 µl Green-Dye
6 ml Assay Buffer (1x)	60 µl Green-Dye

- Streptavidin-HRP:** Before dilution of the concentrated Streptavidin-HRP, add the **Red-Dye** at a dilution of 1:250 (see table below) to the Assay Buffer (1x) used for the final Streptavidin-HRP dilution. Proceed after addition of **Red-Dye** according to the instruction booklet: Preparation of Streptavidin-HRP.

6 ml Assay Buffer (1x)	24 µl Red-Dye
12 ml Assay Buffer (1x)	48 µl Red-Dye

10. Test Protocol


- Predilute your samples before starting with the test procedure. Dilute serum and plasma samples 1:20 with Sample Diluent according to the following scheme:
15 µl sample + 285 µl Sample Diluent
For cell culture supernatants optimal dilutions have to be determined.
- Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Each sample, standard, blank and optional control sample should be assayed in duplicate. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2-8°C sealed tightly.

- c. Wash the microwell strips twice with approximately 400 μl **Wash Buffer** per well with thorough aspiration of microwell contents between washes. Allow the Wash Buffer to sit in the wells for about **10 – 15 seconds** before aspiration. Take care not to scratch the surface of the microwells.

After the last wash step, empty wells and tap microwell strips on absorbent pad or paper towel to remove excess Wash Buffer. Use the microwell strips immediately after washing. Alternatively microwell strips can be placed upside down on a wet absorbent paper for not longer than 15 minutes. **Do not allow wells to dry.**

- d. **Standard dilution on the microwell plate** (Alternatively the standard dilution can be prepared in tubes - see 9.5.1.): Add 100 μl of Sample Diluent in duplicate to all **standard wells**. Pipette 100 μl of prepared **standard** (see Preparation of Standard 9.5., concentration = 100 U/ml) in duplicate into well A1 and A2 (see Table 1). Mix the contents of wells A1 and A2 by repeated aspiration and ejection (concentration of standard 1, S1 = 50 U/ml), and transfer 100 μl to wells B1 and B2, respectively (see Figure 7). Take care not to scratch the inner surface of the microwells. Continue this procedure 4 times, creating two rows of human PSGL-1 standard dilutions ranging from 50.0 to 1.6 U/ml. Discard 100 μl of the contents from the last microwells (F1, F2) used.

Figure 7



In case of an **external standard dilution** (see 9.5.1.), pipette 100 μl of these standard dilutions (S1 - S6) in the standard wells according to Table 1.

Table 1

Table depicting an example of the arrangement of blanks, standards and samples in the microwell strips:

	1	2	3	4
A	Standard 1 (50.0 U/ml)	Standard 1 (50.0 U/ml)	Sample 2	Sample 2
B	Standard 2 (25.0 U/ml)	Standard 2 (25.0 U/ml)	Sample 3	Sample 3
C	Standard 3 (12.5 U/ml)	Standard 3 (12.5 U/ml)	Sample 4	Sample 4
D	Standard 4 (6.3 U/ml)	Standard 4 (6.3 U/ml)	Sample 5	Sample 5
E	Standard 5 (3.1 U/ml)	Standard 5 (3.1 U/ml)	Sample 6	Sample 6
F	Standard 6 (1.6 U/ml)	Standard 6 (1.6 U/ml)	Sample 7	Sample 7
G	Blank	Blank	Sample 8	Sample 8
H	Sample 1	Sample 1	Sample 9	Sample 9

- e. Add 100 μl of **Sample Diluent** in duplicate to the **blank wells**.
- f. Add 100 μl of each prediluted **sample** in duplicate to the **sample wells**.
- g. Prepare **Biotin-Conjugate** (see Preparation of Biotin-Conjugate 9.3.).
- h. Add 50 μl of **Biotin-Conjugate** to all wells.

- i. Cover with an adhesive film and incubate at room temperature (18°C to 25°C) for 2 hours, if available on a microplate shaker set at 100 rpm.
- j. Prepare **Streptavidin-HRP** (refer to Preparation of Streptavidin-HRP 9.4.).
- k. Remove adhesive film and empty wells. **Wash** microwell strips 3 times according to point c. of the test protocol. Proceed immediately to the next step.
- l. Add 100 µl of diluted **Streptavidin-HRP** to all wells, including the blank wells.
- m. Cover with an adhesive film and incubate at room temperature (18°C to 25°C) for 1 hour, if available on a microplate shaker set at 100 rpm.
- n. Remove adhesive film and empty wells. **Wash** microwell strips 3 times according to point c. of the test protocol. Proceed immediately to the next step.
- o. Pipette 100 µl of **TMB Substrate Solution** to all wells.
- p. Incubate the microwell strips at room temperature (18°C to 25°C) for about 10 min. Avoid direct exposure to intense light.

The colour development on the plate should be monitored and the substrate reaction stopped (see next point of this protocol) before positive wells are no longer properly recordable.

Determination of the ideal time period for colour development has to be done individually for each assay.

It is recommended to add the stop solution when the highest standard has developed a dark blue colour. Alternatively the colour development can be monitored by the ELISA reader at 620 nm. The substrate reaction should be stopped as soon as Standard 1 has reached an OD of 0.6–0.65.

- q. Stop the enzyme reaction by quickly pipetting 100 µl of **Stop Solution** into each well. It is important that the Stop Solution is spread quickly and uniformly throughout the microwells to completely inactivate the enzyme. Results must be read immediately after the Stop Solution is added or within one hour if the microwell strips are stored at 2-8°C in the dark.
- r. Read absorbance of each microwell on a spectro-photometer using 450 nm as the primary wave length (optionally 620 nm as the reference wave length; 610 nm to 650 nm is acceptable). Blank the plate reader according to the manufacturer's instructions by using the blank wells. Determine the absorbance of both the samples and the standards.

Note: In case of incubation without shaking the obtained O.D. values may be lower than indicated below. Nevertheless the results are still valid.

11. Calculation of Results

- Calculate the average absorbance values for each set of duplicate standards and samples. Duplicates should be within 20 per cent of the mean value.
- Create a standard curve by plotting the mean absorbance for each standard concentration on the ordinate against the human PSGL-1 concentration on the abscissa. Draw a best fit curve through the points of the graph (a 5-parameter curve fit is recommended).
- To determine the concentration of circulating human PSGL-1 for each sample, first find the mean absorbance value on the ordinate and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the abscissa and read the corresponding human PSGL-1 concentration.
- If instructions in this protocol have been followed serum and plasma samples have been diluted 1:20, the concentration read from the standard curve must be multiplied by the dilution factor (x 20).**
- Calculation of samples with a concentration exceeding standard 1 may result in incorrect, low human PSGL-1 levels (Hook Effect). Such samples require further external predilution according to expected human PSGL-1 values with Sample Diluent in order to precisely quantitate the actual human PSGL-1 level.**
- It is suggested that each testing facility establishes a control sample of known human PSGL-1 concentration and runs this additional control with each assay. If the values obtained are not within the expected range of the control, the assay results may be invalid.
- A representative standard curve is shown in Figure 8. This curve cannot be used to derive test results. Each laboratory must prepare a standard curve for each group of microwell strips assayed.

Figure 8

Representative standard curve for human PSGL-1 ELISA. Human PSGL-1 was diluted in serial 2-fold steps in Sample Diluent. Do not use this standard curve to derive test results. A standard curve must be run for each group of microwell strips assayed.




Table 2

Typical data using the human PSGL-1 ELISA

Measuring wavelength: 450 nm

Reference wavelength: 620 nm

Standard	Human PSGL-1 Concentration (U/ml)	O.D. at 450 nm	Mean O.D. at 450 nm	C.V. (%)
1	50	2.041	2.006	2.5
	50	1.970		
2	25	1.107	1.138	3.8
	25	1.168		
3	12.5	0.502	0.504	0.6
	12.5	0.506		
4	6.3	0.223	0.237	8.1
	6.3	0.225		
5	3.2	0.090	0.089	1.6
	3.2	0.088		
6	1.6	0.048	0.05	4.3
	1.6	0.051		
Blank	0	0.026	0.024	
	0	0.022		

The OD values of the standard curve may vary according to the conditions of assay performance (e.g. operator, pipetting technique, washing technique or temperature effects). Furthermore shelf life of the kit may affect enzymatic activity and thus colour intensity. Values measured are still valid.

12. Limitations

- Since exact conditions may vary from assay to assay, a standard curve must be established for every run.
- Bacterial or fungal contamination of either screen samples or reagents or cross-contamination between reagents may cause erroneous results.
- Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.
- Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Empty wells completely before dispensing fresh wash solution, fill with Wash Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.
- The use of radioimmunotherapy has significantly increased the number of patients with human anti-mouse IgG antibodies (HAMA). HAMA may interfere with assays utilizing murine monoclonal antibodies leading to both false positive and false negative results. Serum samples containing antibodies to murine immunoglobulins can still be analysed in such assays when murine immunoglobulins (serum, ascitic fluid, or monoclonal antibodies of irrelevant specificity) are added to the sample.

13. Performance Characteristics

13.1. Sensitivity

The limit of detection of human PSGL-1 defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations) was determined to be 1.0 U/ml (mean of 6 independent assays).

13.2. Reproducibility

13.2.1. Intra-assay

Reproducibility within the assay was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human PSGL-1. 2 standard curves were run on each plate. Data below show the mean human PSGL-1 concentration and the coefficient of variation for each sample (see Table 3). The calculated overall intra-assay coefficient of variation was 3.2%.

Table 3

The mean human PSGL-1 concentration and the coefficient of variation for each sample

Sample	Experiment	Mean Human PSGL-1 Concentration (U/ml)	Coefficient of Variation (%)
1	1	55.2	1.6
	2	54.5	5.7
	3	62.5	1.4
2	1	45.8	4.4
	2	48.8	1.4
	3	50.7	2.8
3	1	83.6	6.7
	2	94.3	2.7
	3	106.7	0.7
4	1	29.2	9.0
	2	31.5	3.3
	3	33.4	2.8
5	1	58.6	7.3
	2	61.4	1.9
	3	70.2	1.1
6	1	38.1	8.9
	2	42.2	3.3
	3	43.3	0.9

7	1	61.5	2.3
	2	63.9	1.5
	3	64.7	0.7
8	1	66.8	0.8
	2	65.1	4.7
	3	68.2	1.6

13.2.2. Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human PSGL-1. 2 standard curves were run on each plate. Data below show the mean human PSGL-1 concentration and the coefficient of variation calculated on 18 determinations of each sample (see Table 4). The calculated overall inter-assay coefficient of variation was 6.6%.

Table 4

The mean human PSGL-1 concentration and the coefficient of variation of each sample

Sample	Mean Human PSGL-1 Concentration (U/ml)	Coefficient of Variation (%)
1	57.4	7.7
2	48.4	5.1
3	94.8	12.2
4	31.3	6.8
5	63.4	9.5
6	41.2	6.6
7	63.4	2.6
8	66.7	2.3

13.3. Spike Recovery

The spike recovery was evaluated by spiking 4 levels of human PSGL-1 into different pooled normal human serum samples. Recoveries were determined in 3 independent experiments with 4 replicates each. The amount of endogenous human PSGL-1 in unspiked serum was subtracted from the spike values. The recovery ranged from 83% to 104% with an overall mean recovery of 94%.

13.4. Dilution Parallelism

4 serum samples with different levels of human PSGL-1 were analysed at serial 2 fold dilutions with 4 replicates each. The recovery ranged from 88% to 100% with an overall recovery of 96% (see Table 5).

Table 5

Sample	Dilution	Expected Human PSGL-1 Concentration (U/ml)	Observed Human PSGL-1 Concentration (U/ml)	Recovery of Expected Human PSGL-1 Concentration (%)
1	1:20	-	89.8	-
	1:40	44.9	41.2	92
	1:80	22.4	19.7	88
	1:160	11.2	10.2	91
2	1:20	-	117	-
	1:40	58.5	56	96
	1:80	29.3	29	98
	1:160	14.6	15	100
3	1:20	-	97.1	-
	1:40	48.6	47.8	99
	1:80	24.3	23.3	96
	1:160	12.1	11.3	93
4	1:20	-	83.1	-
	1:40	41.5	40.1	97
	1:80	20.8	20.1	97
	1:160	10.4	10.3	99

13.5. Sample Stability

13.5.1. Freeze-Thaw Stability

Aliquots of serum samples (spiked or unspiked) were stored at -20°C and thawed 5 times, and the human PSGL-1 levels determined. There was no significant loss of human PSGL-1 immunoreactivity detected by freezing and thawing.

13.5.2. Storage Stability

Aliquots of serum samples (spiked or unspiked) were stored at -20°C, 2-8°C, room temperature (RT) and at 37°C, and the human PSGL-1 level determined after 24 h. There was no significant loss of human PSGL-1 immunoreactivity detected during storage under above conditions.

13.6. Specificity

The interference of circulating factors of the immune system was evaluated by spiking these proteins at physiologically relevant concentrations into a human PSGL-1 positive serum. There was no crossreactivity detected.

13.7. Expected Values

A panel of 22 serum samples from randomly selected apparently healthy donors (males and females) was tested for human PSGL-1. The detected human PSGL-1 levels ranged between 329.8 and 762.5 U/ml with a mean level of 451.0 U/ml. The levels measured may vary with the sample collection used.

14. Bibliography

1. Andrews R.K., et al. Molecular mechanisms of platelet adhesion and activation. *Int J Biochem Cell Biol.* 1997 Jan; 29(1): 91-105.
2. Asa D., et al. The P-selectin glycoprotein ligand functions as a common human leukocyte ligand for P- and E-selectins. *J Biol Chem.* 1995 May 12; 270(19): 11662-11670.
3. Blanks J.E., et al. Stimulation of P-selectin glycoprotein ligand-1 on mouse neutrophils activates beta 2-integrin mediated cell attachment to ICAM-1. *Eur J Immunol.* 1998 Feb; 28(2): 433-443.
4. Borges E., et al. P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T helper 2 cells binds to P-selectin and supports migration into inflamed skin. *J Exp Med.* 1997 Feb 3; 185(3): 573-578.
5. Borges E., et al. The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated. *J Biol Chem.* 1997 Nov 7; 272(45): 28786-28792.
6. De Luca M., et al. A novel cobra venom metalloproteinase, mocarhagin, cleaves a 10-amino acid peptide from the mature N terminus of P-selectin glycoprotein ligand receptor, PSGL-1, and abolishes P-selectin binding. *J Biol Chem.* 1995 Nov 10; 270(45): 26734-26737.
7. Dulkanchainun T.S., et al. Reduction of hepatic ischemia/reperfusion injury by a soluble P-selectin glycoprotein ligand-1. *Ann Surg.* 1998 Jun; 227(6): 832-840.
8. Fujimoto T.T., et al. Expression and functional characterization of the P-selectin glycoprotein ligand-1 in various cells. *Int J Hematol.* 1996 Oct; 64(3-4): 231-239.
9. Furie B., et al. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. *Thromb Haemost.* 1995 Jul; 74(1): 224-227.
10. Fuhlbrigge R.C., et al. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. *Nature.* 1997 Oct 30; 389(6654): 978-981.
11. Goetz D.J., et al. A human colon carcinoma cell line exhibits adhesive interactions with P-selectin under fluid flow via a PSGL-1-independent mechanism. *Am J Pathol.* 1996 Nov; 149(5): 1661-1673.
12. Goetz D.J., et al. Isolated P-selectin glycoprotein ligand-1 dynamic adhesion to P- and E-selectin. *J Cell Biol.* 1997 Apr 21; 137(2): 509-519.
13. Guyer D.A., et al. P-selectin glycoprotein ligand-1 (PSGL-1) is a ligand for L-selectin in neutrophil aggregation. *Blood.* 1996 Oct 1; 88(7): 2415-2421.
14. Guyer D.A., et al. P-selectin glycoprotein ligand-1 (PSGL-1) is a ligand for L-selectin in neutrophil aggregation. *Blood.* 1996 Oct 1; 88(7): 2415-2421.
15. Hidari K.I., et al. Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils. *J Biol Chem.* 1997 Nov 7; 272(45): 28750-28756.
16. Hirose M., et al. A functional epitope on P-selectin that supports binding of P-selectin to P-selectin glycoprotein ligand-1 but not to sialyl Lewis X oligosaccharides. *Int Immunol.* 1998 May; 10(5): 639-649.
17. Kaytes P.S., et al. P-selectin mediates adhesion of the human melanoma cell line NKI-4: identification of glycoprotein ligands. *Biochemistry.* 1998 Jul 21; 37(29): 10514-10521.
18. Laszik Z., et al. P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells. *Blood.* 1996 Oct 15; 88(8): 3010-3021.

19. Lawrence M.B., et al. Threshold levels of fluid shear promote leukocyte adhesion through selectins. *J Cell Biol.* 1997 Feb 10; 136(3): 717-727.
20. Li F., et al. Visualization of P-selectin glycoprotein ligand-1 as a highly extended molecule and mapping of protein epitopes for monoclonal antibodies. *J Biol Chem.* 1996 Mar 15; 271(11): 6342-6348.
21. Li F., et al. Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin. *J Biol Chem.* 1996 Feb 9; 271(6): 3255-3264.
22. Liu W., et al. Identification of N-terminal residues on P-selectin glycoprotein ligand-1 required for binding to P-selectin. *J Biol Chem.* 1998 Mar 20; 273(12): 7078-7087.
23. McEver R.P. Regulation of function and expression of P-selectin. *Agents Actions Suppl.* 1995; 47: 117-119
24. McEver R.P., et al. Role of PSGL-1 binding to selectins in leukocyte recruitment. *J Clin Invest.* 1997 Dec 1; 100(11 Suppl): S97-S103
25. McEver R.P., et al. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. *J Clin Invest.* 1997 Aug 1; 100(3): 485-491.
26. Mehta P., et al. Soluble monomeric P-selectin containing only the lectin and epidermal growth factor domains binds to P-selectin glycoprotein ligand-1 on leukocytes. *Blood.* 1997 Sep 15; 90(6): 2381-2389.
27. Moore K.L. Structure and function of P-selectin glycoprotein ligand-1. *Leuk Lymphoma.* 1998 Mar; 29(1-2): 1-15.
28. Moore K.L., et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. *J Cell Biol.* 1995 Feb; 128(4): 661-671.

29. Moore K.L., et al. The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine. *J Biol Chem.* 1994 Sep 16; 269(37): 23318-23327.
30. Norman K.E., et al. Leukocyte rolling in vivo is mediated by P-selectin glycoprotein ligand-1. *Blood.* 1995 Dec 15; 86(12): 4417-4421.
31. Patel K.D., et al. Comparison of tethering and rolling of eosinophils and neutrophils through selectins and P-selectin glycoprotein ligand-1. *J Immunol.* 1997 Nov 1; 159(9): 4555-4565.
32. Pouyani T., et al. PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation consensus at the PSGL-1 amino terminus. *Cell.* 1995 Oct 20; 83(2): 333-343.
33. Ramos C.L., et al. Functional characterization of L-selectin ligands on human neutrophils and leukemia cell lines: evidence for mucinlike ligand activity distinct from P-selectin glycoprotein ligand-1. *Blood.* 1998 Feb 1; 91(3): 1067-1075.
34. Sako D., et al. Expression cloning of a functional glycoprotein ligand for P-selectin. *Cell.* 1993 Dec 17; 75(6): 1179-1186.
35. Sako D., et al. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. *Cell.* 1995 Oct 20; 83(2): 323-331.
36. Snapp K.R., et al. Dimerization of P-selectin glycoprotein ligand-1 (PSGL-1) required for optimal recognition of P-selectin. *J Cell Biol.* 1998 Jul 13; 142(1): 263-270.
37. Snapp K.R., et al. A novel P-selectin glycoprotein ligand-1 monoclonal antibody recognizes an epitope within the tyrosine sulfate motif of human PSGL-1 and blocks recognition of both P- and L-selectin. *Blood.* 1998 Jan 1; 91(1): 154-164.
38. Snapp K.R., et al. P-selectin glycoprotein ligand-1 is essential for adhesion to P-selectin but not E-selectin in stably transfected hematopoietic cell lines. *Blood.* 1997 Feb 1; 89(3): 896-901.

39. Symon F.A., et al. Functional and structural characterization of the eosinophil P-selectin ligand. *J Immunol.* 1996 Aug 15; 157(4): 1711-1719.
40. Tu L., et al. L-selectin binds to P-selectin glycoprotein ligand-1 on leukocytes: interactions between the lectin, epidermal growth factor, and consensus repeat domains of the selectins determine ligand binding specificity. *J Immunol.* 1996 Nov 1; 157(9): 3995-4004.
41. Vachino G., et al. P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. *J Biol Chem.* 1995 Sep 15; 270(37): 21966-21974.
42. Veldman G.M., et al. Genomic organization and chromosomal localization of the gene encoding human P-selectin glycoprotein ligand. *J Biol Chem.* 1995 Jul 7; 270(27): 16470-16475.
43. Walcheck B., et al. Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1. A mechanism that amplifies initial leukocyte accumulation of P-selectin *in vitro*. *J Clin Invest.* 1996 Sep 1; 98(5): 1081-1087.
44. Wardlaw A.J., et al. Adhesion interactions involved in eosinophil migration through vascular endothelium. *Ann N Y Acad Sci.* 1996 Oct 31; 796: 124-137.
45. Wilkins P.P., et al. Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin. *J Biol Chem.* 1995 Sep 29; 270(39): 22677-22680.

15. Reagent Preparation Summary

15.1. Wash Buffer (1x)

Add **Wash Buffer Concentrate** 20x (50 ml) to 950 ml distilled water.

Number of Strips	Wash Buffer Concentrate (ml)	Distilled Water (ml)
1 – 6	25	475
1 - 12	50	950

15.2. Assay Buffer (1x)

Add **Assay Buffer Concentrate** 20x (5 ml) to 95 ml distilled water.

Number of Strips	Assay Buffer Concentrate (ml)	Distilled Water (ml)
1 – 6	2.5	47.5
1 - 12	5.0	95.0

15.3. Biotin-Conjugate

Make a 1:100 dilution of **Biotin-Conjugate** in Assay Buffer (1x):

Number of Strips	Biotin-Conjugate (ml)	Assay Buffer (1x) (ml)
1 – 6	0.03	2.97
1 - 12	0.06	5.94

15.4. Streptavidin-HRP

Make a 1:200 dilution of **Streptavidin-HRP** in Assay Buffer (1x):

Number of Strips	Streptavidin-HRP (ml)	Assay Buffer (1x) (ml)
1 – 6	0.03	5.97
1 - 12	0.06	11.94

15.5. Human PSGL-1 Standard

Reconstitute lyophilized **human PSGL-1 standard** with distilled water. (Reconstitution volume is stated on the label of the standard vial.)

16. Test Protocol Summary

1. Predilute serum and plasma samples with Sample Diluent 1:20.
2. Determine the number of microwell strips required.
3. Wash microwell strips twice with Wash Buffer.
4. Standard dilution on the microwell plate: Add 100 µl Sample Diluent, in duplicate, to all standard wells. Pipette 100 µl prepared standard into the first wells and create standard dilutions by transferring 100 µl from well to well. Discard 100 µl from the last wells.
Alternatively external standard dilution in tubes (see 9.5.1.): Pipette 100 µl of these standard dilutions in the microwell strips.
5. Add 100 µl Sample Diluent, in duplicate, to the blank wells.
6. Add 100 µl prediluted sample in duplicate, to designated sample wells.
7. Prepare Biotin-Conjugate.
8. Add 50 µl Biotin-Conjugate to all wells.
9. Cover microwell strips and incubate 2 hours at room temperature (18°C to 25°C).
10. Prepare Streptavidin-HRP.
11. Empty and wash microwell strips 3 times with Wash Buffer.
12. Add 100 µl diluted Streptavidin-HRP to all wells.
13. Cover microwell strips and incubate 1 hour at room temperature (18°C to 25°C).
14. Empty and wash microwell strips 3 times with Wash Buffer.
15. Add 100 µl of TMB Substrate Solution to all wells.
16. Incubate the microwell strips for about 10 minutes at room temperature (18°C to 25°C).
17. Add 100 µl Stop Solution to all wells.
18. Blank microwell reader and measure colour intensity at 450 nm.

Note: If instructions in this protocol have been followed serum and plasma samples have been diluted 1:20, the concentration read from the standard curve must be multiplied by the dilution factor (x 20).

17. Ordering Information

Product Name	Product Description	Size	Catalog Number
sPSGL-1 (sCD162) ELISA Kit, human	Human soluble P-selectin Glycoprotein Ligand 1 (sCD162) ELISA Kit	96 Tests	PK-EL-66566

***For in vitro research use only.
Not for diagnostic or therapeutic procedures.***

PromoCell GmbH

Sickingenstr. 63/65
69126 Heidelberg
Germany

North America

Phone: 1 – 866 – 251 – 2860 (toll free)
Fax: 1 – 866 – 827 – 9219 (toll free)

Deutschland

Telefon: 0800 – 776 66 23 (gebührenfrei)
Fax: 0800 – 100 83 06 (gebührenfrei)

France

Téléphone: 0800 90 93 32 (ligne verte)
Téléfax: 0800 90 27 36 (ligne verte)

United Kingdom

Phone: 0800 – 96 03 33 (toll free)
Fax: 0800 – 169 85 54 (toll free)

Other Countries

Phone: +49 6221 – 649 34 0
Fax: +49 6221 – 649 34 40

Email: info@promokine.info